Impax cuts 110 jobs, expects to save $15 million

(Reuters) – Impax Laboratories Inc said it cut about 110 jobs, or 10 percent of its workforce, mainly in its Hayward, California plant, more than four months after U.S. health regulators denied approval to the company’s Parkinson’s drug citing concerns about the manufacturing practices at the plant. The company said in early March that the U.S. Food and Drug Administration had re-inspected the facility and made 12 observations, three of which had been raised previously. The FDA denied approval to Impax’s experimental Parkinson’s disease drug, Rytary, in January. …